Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02004392 · ClinicalTrials.gov registry record · Phase 3
Study of the Safety and Clinical Effects of 2 Doses of EVP-6124 in Subjects With Alzheimer's Disease Who Complete Study EVP-6124-024 or EVP-6124-025
A Phase 3 study, sponsored by FORUM Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 348
- Enrollment target
NCT02004392 is a Phase 3 study that was terminated before completion, run by FORUM Pharmaceuticals. The registered enrollment target is 348 participants.
The verdict
NCT02004392, a Phase 3 study, was terminated before completion, sponsored by FORUM Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 348 participants
- Enrollment target
Study Summary
This is a 26-week, randomized extension of the Phase 3 double-blind placebo-controlled studies, EVP-6124-024 and EVP-6124-025. In this extension study, subjects who complete study EVP-6124-024 or EVP-6124-025 and fulfill all entry criteria will be randomized to receive EVP-6124 for an additional 26 weeks.
Interventions
- DRUG EVP-6124
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 348 participants |
| Start Date | 2014-06 |
| Est. Completion | 2017-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02004392
The ClinicalTrials.gov registry entry for NCT02004392 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 348 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is FORUM Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which EVP-6124 is the first listed.
NCT02004392 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02004392 about?
NCT02004392 is a clinical study titled "Study of the Safety and Clinical Effects of 2 Doses of EVP-6124 in Subjects With Alzheimer's Disease Who Complete Study EVP-6124-024 or EVP-6124-025". This is a 26-week, randomized extension of the Phase 3 double-blind placebo-controlled studies, EVP-6124-024 and EVP-6124-025. In this extension study, subjects who complete study EVP-6124-024 or EVP-6124-025 and fulfill all entry criteria will be randomized to receive EVP-6124 for an additional 26 ...
What is the current status of trial NCT02004392?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 348 participants. The study started on 2014-06. Estimated completion is 2017-08.
What interventions are being tested in trial NCT02004392?
The interventions under investigation include: EVP-6124 (DRUG).
Who is sponsoring clinical trial NCT02004392?
This trial is sponsored by FORUM Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.